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We performed a randomized trial to determine whether albumin should be administered to




91We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP in-
fections, andadditional risk factors forpooroutcomewere randomly assigned to receive antibiotics
plus albumin (study group; n [ 61) or antibiotics alone (control group; n [ 57). The primary








101There were no significant differences at baseline between groups in results from standard
laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity
scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney
dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group;
P [ .02), indicating greater baseline overall severity. There was no significant difference in the
primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P[
.66). Circulatory and renal functions improved in only the study group. A significantly higher
proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control
group; P [ .03). A significantly lower proportion of patients in the study group developed





107In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital
mortality was similar between those who received albumin plus antibiotics vs those who
received only antibiotics (controls). However, patients given albumin were sicker at baseline
and, during the follow-up period, a higher proportion had ACLF resolution and a lower pro-
portion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.108
109Keywords: Acute-on-Chronic Liver Failure; Mortality; Nosocomial Infections; Immune-Modulation.110er: ACLF, acute-on-chronic liver failure;
hepatorenal syndrome; IL, interleukin; ITT,
dysfunction; RCT, randomized controlled
ial peritonitis; UTI, urinary tract infection;
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What You Need to Know
Background
We performed a randomized trial to determine
whether albumin should be administered to patients
with infections unrelated to spontaneous bacterial
peritonitis (SBP).
Findings
Among patients with advanced cirrhosis and non-SBP
infections, in-hospital mortality is similar between
those who receive the combination of albumin and
antibiotics and those who received only antibiotics.
However, a higher proportion of patients given al-
bumin have resolution of acute on chronic liver fail-
ure and a lower proportion develop nosocomial
infections.
Implications for Patient Care
Patients with advanced cirrhosis and non-SBP in-
fections who receive the combination of albumin and
antibiotics have better outcomes than patients who
received only antibiotics.




























































































208The transition from compensated to decom-pensated cirrhosis occurs in the setting of an
activation of the immune system, chronic systemic
inflammation, and multiorgan dysfunction.1–4 Systemic
inflammation induces an immune-modulatory response
that increases the risk of infection.5 When infection de-
velops in decompensated cirrhosis, there is a secondary
burst of inflammation,1–5 which may lead to the develop-
ment of acute-on-chronic liver failure (ACLF).
The pioneer randomized controlled trial (RCT)6 done
in patients with spontaneous bacterial peritonitis (SBP)
showing that intravenous albumin reduced the preva-
lence of type-1 hepatorenal syndrome (HRS) and hospital
mortality, introduced the prophylactic use of albumin in
patients with bacterial infections. However, 2 subsequent
negative RCTs in patients with non-SBP infections sug-
gested that the beneficial effects of albumin did not
extend to all types of infections.7,8 However, short-term
mortality rates were very low in both studies (5%).
We performed a retrospective analysis of 3 cohorts to
identify patients with cirrhosis and non-SBP infections at
higher risk of hospital mortality.9 Mortality was highly
dependent of the type of infection: high in endocarditis
and secondary peritonitis, intermediate in pneumonia
and bacteremia, and low in urinary tract infection (UTI)
and cellulitis. Hospital mortality rate of each type of
infection was significantly higher in patients with poor
liver/renal function.
Based on these data, we designed an RCT aimed to
assess if albumin treatment impacted hospital survival
among patients with cirrhosis with non-SBP infections at
high risk of hospital mortality. The secondary endpoint


























The INFECIR-2 Albumin Prevention study (Albumin
administration in the prevention of HRS and death in
patients with cirrhosis, bacterial infections other than
SBP and high risk of hospital mortality; ClinicalTrials.
gov: NCT02034279) is an EASL-CLIF Consortium
investigator-initiated, phase IV, randomized, open-
label, parallel, multicenter European trial promoted
by the Fundació Clínic (Hospital Clínic, University of
Barcelona, Barcelona, Spain). Written informed con-
sent was obtained from all patients. All authors had
access to the study data, critically reviewed the
manuscript, and approved the final draft. The trial
was performed in 27 centers, in accordance with the
Declaration of Helsinki, and was approved by the
different local ethics committees and competent
authorities.FLA 5.6.0 DTD  YJCGH56661_proof  2Patients
Inclusion criteria. Patients with non-SBP infections
were screened for eligibility. Inclusion criteria were: age
18 years; liver cirrhosis; UTI, pneumonia, sponta-
neous/secondary bacteremia, cellulitis, acute cholangitis,
or suspected bacterial infection; and advanced liver
disease (serum creatinine 1.2 mg/dL, serum sodium
130 mEq/L, and/or serum bilirubin 4 mg/dL). Pa-
tients with pneumonia or spontaneous/secondary
bacteremia required the presence of at least 1 of these
criteria (serum creatinine 1.2 mg/dL, serum sodium
130 mEq/L, or serum bilirubin 4 mg/dL)9; in the rest,
at least 2 were required. Patients with UTI or suspected
infections required additionally at least 1 diagnostic
criterion of systemic inflammatory response syndrome
(temperature >38C or <36C; heart rate >90 beats/
minute; respiratory rate >20 breaths/minute; white
blood cell (WBC) count >12.000 or <4000/mm3); and a
serum C reactive protein (CRP) level 1 mg/dL.
Exclusion criteria. The main exclusion criteria were:
infections evolving for >72 hours, septic shock, endo-
carditis, severe acute respiratory distress syndrome
(PaO2/FIO2 100), active/recent variceal bleeding (un-
less controlled for >48 hours), type-1 HRS (IAC criteria),
ACLF grade-3, malignancy (except for hepatocellular
carcinoma within Milan criteria or nonmelanocytic skin
cancer), chronic heart failure (New York Heart Associa-
tion functional class II-IV), severe chronic pulmonary
disease (Global Initiative for Chronic Obstructive Lung
Disease IV), liver transplantation, human immunodefi-
ciency virus infection, contraindications to albumin,7 September 2019  12:10 am  ce CJ
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348albumin administration (80 g) in the last 2 days, and
SBP coinfection. All exclusion criteria are detailed in the
Supplementary Material.
Randomization
Randomization was performed in blocks of 4 (1:1
ratio). It was centralized at the Data Management Center
of the European Foundation for the Study of Chronic
Liver Failure, was independent for each center, and
performed online. A computer-generated randomization
list (block sizes blinded for the investigators) was used
for treatment allocation. Blocks were stratified by the
type (pneumonia vs other infections) and the site of
acquisition of infection (nosocomial vs other).
Treatment Allocation, Study Protocol, and
Follow-Up
Eligible patients were randomized to receive antibi-
otics alone (control group) or antibiotics plus albumin
(study group). Suggestions for the choice of empirical
antibiotics were given in the study protocol
(Supplementary Material). The study albumin (Albutein
20%, Instituto Grifols) was administered at a dose of 1.5
g/kg body weight at Day 1 and 1 g/kg body weight at
Day 3 up to a maximum of 150 g and 100 g, respectively,
in patients with body weight >100 kg, and a minimum of
90 g and 60 g, respectively, in patients with body weight
<60 kg. Albumin administration was started within the
first 8 hours after randomization and infused in 6–12
hours with close clinical monitoring to prevent volume
overload. Follow-up visits were performed on Days 3 and
7, and weekly thereafter until infection resolution. Data
on liver transplantation, hospital and 90-day mortality,
and causes of death were recorded within 3 months after
enrollment. No other doses of albumin were allowed in
both treatment arms throughout the hospitalization un-
less needed for the treatment of type-1 HRS, total para-
centesis, or SBP.
As per protocol, routine laboratory tests, serum al-
bumin levels, and plasma concentration of interleukin 6
(IL6) and renin (PRC) were measured at Days 1 and 3
(before albumin doses in the group) and at infection
resolution or Day 7. PRC and IL6 were measured by
chemiluminescent immunoassay and enzyme-linked
immunosorbent assay, respectively.
Assessment of Disease Severity at Enrollment
and Definitions
We enrolled patients with prespecified criteria for
advanced cirrhosis.10 Disease severity at enrollment was
estimated by standard tests, Child-Pugh, Model for End-
Stage Liver Disease, and CLIF-Consortium organ failure
scores11 (Supplementary Table 1) and by the presence of
ACLF or kidney dysfunction (KD). Reasons forFLA 5.6.0 DTD  YJCGH56661_proof  2considering these 2 later variables to assess disease
severity are described in the Supplementary Material
and in Supplementary Tables 2 and 3.
Definitions and diagnostic criteria of ACLF and bac-
terial infections are also detailed in the Supplementary
Material.Study Outcomes
The prespecified primary outcome was mortality in
hospital. Secondary outcomes were: the grade of circu-
latory dysfunction (as estimated by PRC), systemic
inflammation (as estimated by plasma concentration of
IL6 and other biomarkers) and complications related
with these abnormalities (ACLF and nosocomial bacterial
infections), and 90-day mortality. We also sought to
identify predictors of in-hospital and 90-day mortality,
and development of ACLF, bacterial infection, and pul-
monary edema during hospitalization.Statistical Analysis
Unless specified, analyses were performed on an
intention-to-treat (ITT) basis. In-hospital mortality was
estimated to be about 29% in patients who did not
receive albumin. Based on this assumption, a global
sample size of 512 patients (256 per treatment arm) was
estimated to detect an absolute reduction of 11% (18%
mortality rate) in patients treated with albumin (80%
statistical power).6,9 A 2-way 5% type-I error and a 10%
drop-out rate was assumed.
Statistical analysis was performed using unpaired
Student t test for continuous variables with parametric
distribution, Mann-Whitney U test for those with
nonparametric distribution, and chi-square test for
qualitative variables, applying Yate correction when
required. Differences were considered significant at the
level 0.05. Survival was analyzed by Kaplan-Meier
method and compared between groups with log-rank
test. Risk factors were assessed using univariate anal-
ysis, and variables that were significantly associated with
the different outcome events were included in the
multivariate analysis by fitting logistic regression models
to obtain adjusted treatment estimates and independent
risk factors (forward stepwise selection method).
Competing risk analyses were used to evaluate the
impact of albumin treatment on the primary outcome,
estimating the cumulative incidence of death at hospital
discharge, whereas liver transplantation was treated as a
competing event. Competing risk analysis was also used
to estimate the cumulative incidence of new proven
bacterial infection during hospitalization in both treat-
ment arms. Liver transplantation was treated again as a
competing event. The estimated cumulative incidences
were compared by means of the Gray test. Analysis was
done with SPSS version 18.0 (IBM, Armonk, NY) and SAS
version 9.1 (SAS Institute, Cary, NC).7 September 2019  12:10 am  ce CJ












Age, y 58.3  13.7 58.5  11.0 .92
Male sex, n (%) 35 (58.3) 39 (66.1) .38
Alcoholic cirrhosis,
n (%)
31 (50.8) 39 (68.4) .05
Diabetes mellitus,
n (%)
21 (35.0) 17 (28.8) .47




28 (46.7) 27 (45.8) .92
Mean arterial pressure,
mm Hg





5.9 (6.2) 7.3 (6.8) .25
Serum albumin, g/L 23.6  9.1 24.0  8.4 .78
Prothrombin ratio, % 49.6  13.0 48.9  16.5 .82
Serum creatinine,
mg/dL
1.27  0.66 1.13  0.38 .16
Serum sodium, mEq/L 131.1  6.2 132.8  5.4 .12
Serum bilirubin
4 mg/dL, %
33 (55.9) 36 (63.2) .43
Serum creatinine 1.2
mg/dL, %
32 (53.3) 28 (49.1) .65
Serum sodium <130
mEq/L, %











White blood cell count,
109/L
7.2 (4.8–10.5) 6.9 (4.9–10.1) .95
Serum C-reactive
protein, mg/dL
12.7 (4.6–46.5) 15.8 (6.4–42.1) .63
Plasma interleukin 6,
pg/mL




242 (46–903) 125 (34–399) .29
Presence of ACLF or
kidney dysfunction,
n (%)
ACLF-1 13 (21.3) 8 (14.0) .63
ACLF-2 4 (6.6) 1 (1.8)
ACLF 17 (27.9) 9 (15.8) .11
Kidney dysfunction 10 (16.4) 5 (8.8) .21
ACLF or kidney
dysfunction




10.4  9.8 10.5  10.0 .77
19.3  5.5 19.8  5.1 .60
FLA 5.6.0 DTD  YJCGH56661_proof  27 September 2019  12:10 am  ce CJ




































































































































7.4  1.7 7.5  1.6 .77
Site and severity of
infection, n (%)




15 (24.6) 11 (19.3) .49
Urinary tract infection 12 (19.7) 8 (14.0) .41
Cellulitis 2 (3.3) 6 (10.5) .15
Cholangitis 3 (4.9) 0 .24
Unproven infections 10 (16.4) 9 (15.8) .93
Othera 2 (3.2) 1 (1.8) 1.0
Presence of sepsis 35 (57.4) 28 (49.1) .37
Site of acquisition of
infection, n (%)
Community-acquired 27 (45.8) 25 (42.4) .78
Health care–associated 14 (23.3) 15 (25.0)
Nosocomial 18 (30.0) 19 (31.7)
Results of microbial
culture, n (%)
Culture-positive 31 (50.8) 32 (56.1) .56
Presence of multidrug-
resistant bacteria
10 (16.4) 14 (24.6) .27
NOTE. Plus–minus values are means  SD. Analyses were performed on an intention-to-treat basis.
ACLF, acute-on-chronic liver failure.
aOne cholecystitis and 1 Clostridium difficile infection occurred in the albumin-plus-antibiotics group, and 1 spontaneous bacterial empyema in the antibiotics-
alone group.





















































































































Patients’ enrollment. The study was started on
September 1, 2014, and finished in December 31, 2016.
Overall, of the 534 patients who were screened from
September 2014 to April 2016, 433 were excluded (in-
clusion rate, 19%). Thereafter, investigators were
instructed to record only those patients included. Finally,
a total of 136 patients were enrolled and 18 were
considered inclusion errors (Supplementary Figure 1).
The final ITT population consisted of 118 patients, 61 in
the study group and 57 in the control group.
Demographic characteristics and clinical data. The
prevalence of alcoholic cirrhosis was higher in the con-
trol group (68.4% vs 50.8% in the study group; P ¼ .05)
(Table 1). There were no differences in other de-
mographic or clinical data.
Severity of cirrhosis and systemic inflammation. There
were no significant differences between groups in stan-
dard liver and renal function tests and liver scores
(Table 1). However, the combined prevalence of ACLF
and KD was significantly higher in the study groupFLA 5.6.0 DTD  YJCGH56661_proof  2(44.3% vs 24.6%; P ¼ .025), suggesting significantly
higher disease severity.
The grade of circulatory dysfunction (PRC) was also
similar between groups as well as the severity of sys-
temic inflammation, as estimated by WBC count, plasma
IL6 concentrations, and serum CRP levels.
Type, severity, and microbiology of bacterial infec-
tions. Median time from diagnosis of infection to study
inclusion was 1 day in both groups. Pneumonia, bacter-
emia, and UTI were the most frequent infections. Sixty-
three patients showed signs of sepsis. Infections were
community acquired in 52 patients (Table 1). Half of the
infections were associated with positive cultures (24
were caused by multiresistant bacteria). There were no
significant differences between groups in the type, site of
acquisition, severity, and microbiology of infections
(Supplementary Material and Supplementary Table 4).Albumin Administration
All except 5 patients in the study group received the
scheduled doses of 20% albumin on Days 1 and 3. Four
patients did not receive albumin on Day 3 because of
pulmonary edema (n ¼ 3) or septic shock (n ¼ 1).7 September 2019  12:10 am  ce CJ
580
Table 2. Effects of Treatment on Standard Laboratory Tests, Biomarkers of Systemic Inflammation and Circulatory

















Serum albumin and liver, kidney,
and circulatory function
Serum albumin, g/L
Baseline 25.9  6.4 26.0  5.7
Day 3–7 31.2  6.5 < .0001 25.8  5.3 .5414 < .001
Median value for serum
bilirubin (IQR), mg/dL
Baseline 4.3 (1.7–7.8) 5.1 (2.1–11.0)
Day 3–7 4.0 (2.3–8.7) .8120 4.3 (1.7–9.7) .0274 .18
Prothrombin ratio, %
Baseline 49.6  13.0 48.9  16.5
Day 3–7 48.1  14.2 .3793 49.5  16.1 .4155 .16
Serum creatinine, mg/dL
Baseline 1.3  0.7 1.1  0.4
Day 3–7 1.1  0.6 .0116 1.1  0.4 .1513 .18
Serum sodium, mEq/L
Baseline 131.2  6.2 132.7  5.4
Day 3–7 134.9  5.7 < .0001 133.5  5.1 .0905 .002
Mean arterial pressure, mm Hg
Baseline 78.1  11.7 79.1  11.0
Day 3–7 82.1  11.8 .0167 80.1  10.5 .4758 .18
Median value for plasma renin
concentration (IQR), mIU/md
Baseline 242 (46–903) 125 (34–399)
Day 3–7 161 (18–393) .0002 91 (25–768) .4426 .004
Median value for markers of
inflammation (IQR)
White blood cell count, 109/L
Baseline 7.2 (4.8–10.5) 6.9 (4.9–10.1)
Day 3–7 5.8 (3.9–9.0) .0003 6.2 (4.3–10.0) .1347 .14
Serum C-reactive protein,
mg/dL
Baseline 12.7 (4.6–46.5) 15.8 (6.4–42.1)
Day 3–7 8.7 (3.0–28.0) < .0001 11.5 (3.8–33.4) < .0001 .81
Plasma interleukin 6, pg/mLe
Baseline 37 (21–155) 41 (24–108)
Day 3–7 32 (18–69) .0322 32 (17–72) .2900 .71
Course of infection, n (%)
Adequate empirical antibiotics 55 (90.2) — 51 (89.5) — .90
Septic shock 6 (9.8) — 2 (3.5) — .17
Infection resolution 53 (89.8) — 54 (96.4) — .27
Course of ACLF or kidney
dysfunction, n/N (%)
Resolution of ACLFf 14/17 (82.3) — 3/9 (33.3) — .03
Resolution of kidney dysfunction 7/10 (70.0) — 3/5 (60.0) — .28
Resolution of ACLF or kidney
dysfunction
21/27 (77.8) — 6/14 (42.9) — .03
NOTE. Plus–minus values are means  SD. Analyses were performed on an intention-to-treat basis.
ACLF, acute-on-chronic liver failure; IQR, interquartile range.
aComparison of baseline vs Day 3–7, in the albumin-plus-antibiotics group.
bComparison of baseline vs Day 3–7, in the antibiotics-alone group.
cBetween group comparison was performed at Day 3–7.
dPlasma renin concentrations were determined at Day 1, and Day 3–7 in 40 patients in the albumin-plus-antibiotics group and in 41 patients in the antibiotics-alone
group.
eInterleukin 6 levels were determined at Day 1, and Day 3–7 in 48 patients in the albumin-plus-antibiotics group and in 47 patients in the antibiotics-alone group.
fThe 4 patients with ACLF-2 in the albumin-plus-antibiotics group solved the syndrome; this did not occur in the single patient with ACLF-2 of the antibiotics-alone
group.
FLA 5.6.0 DTD  YJCGH56661_proof  27 September 2019  12:10 am  ce CJ



































































































































Figure 1. Albumin therapy in patients with advanced cirrhosis and non-SBP infections induces multifaceted beneficial effects
but no increase in survival. (A) Individual changes in serum albumin concentration during treatment. Serum albumin con-
centration increased significantly only in patients receiving albumin; P < .001 for the between-group comparison. (B) Individual
changes in PRC during treatment. Albumin treatment was associated with a marked reduction in PRC; P ¼ .004 for the
between-group comparison. (C) Individual changes in WBC during treatment. WBC decreased in both groups, but differences
were statistically significant only in patients receiving albumin; P value not significant (0.14) for the between-group comparison.
(D) Clinical course of ACLF diagnosed at enrollment. It resolved more frequently in patients receiving albumin. (E) Cumulative
incidence of new proven bacterial infections was significantly higher in the control group. (F) Cumulative incidence of death
was similar between groups. Liver transplantation was considered as a competing risk of bacterial infection development and
death. In every panel, blue color represents patients treated with albumin and antibiotics, and red color those treated with
antibiotics alone. ALB-G; PRC; SMT-G Q10.
FLA 5.6.0 DTD  YJCGH56661_proof  27 September 2019  12:10 am  ce CJ


























































































































(n ¼ 57) P value
New bacterial infections
Patients with infections, n (%)
Patients with proven or unproven infections, n (%) 6 (9.8) 14 (24.6) .03
Patients with proven infections, n (%) 4 (6.6) 14 (24.6) .007
Type and severity of infections, n (%) .27
Pneumonia 1 (1.6) 4 (7.0)
Spontaneous or secondary bacteremia 1 (1.6) 4 (7.0)
Urinary tract infection 1 (1.6) 3 (5.3)
Spontaneous bacterial peritonitis 1 (1.6) 0
Cellulitis 1 (1.6) 2 (3.5)
Unproven infections 2 (3.3) 0
Clostridium difficile infection 0 2 (3.5)
Other 0 1 (1.8)
Number of infectious episodes 7 16
Presence of sepsis 4 (6.6) 6 (10.5) .44
Microbiology and course of infection,
n (% of infections)
Culture positivea 1 (14.3) 10 (62.5) .07
Multidrug-resistant bacteria 1 (14.3) 7 (43.8) .34
Adequate empirical antibiotics 4 (57.1) 14 (87.5) .14
Septic shock 2 (28.6) 5 (31.3) .38
Infection resolution 4 (57.1) 12 (75.0) .63
New episodes of ACLF, n (%)
Patients with ACLF, n (%)
ACLF-1 6 (9.8) 6 (10.5) .86
ACLF-2 5 (8.2) 5 (8.8)
ACLF-3 1 (1.6) 2 (3.5)
Overall ACLF 12 (19.7) 13 (22.8) .68
Potential mechanisms of the new ACLF .17
Recurrence of a resolved ACLF 2 (3.3) 0
Precipitated by baseline bacterial infectionb 5 (8.2) 5 (8.8)
Precipitated by new bacterial infection 1 (1.6) 4 (7.0)
Unknown mechanism 4 (6.6) 4 (7.0)
Course of ACLF
Resolution 3 (4.9) 6 (10.5) .39
Other clinical events, n (%)
Variceal bleeding 4 (6.6) 2 (3.5) .45
Nonvariceal bleeding 4 (6.3) 3 (5.3) .77
Atrial fibrillation 2 (3.3) 0 .50
Pulmonary edema 4 (6.6) 2 (3.5) .45
Liver transplantation and mortality, n (%)
Liver transplantation during hospitalization 1 (1.6) 4 (7.0) .20
Liver transplantation by 90 days 2 (3.3) 6 (10.5) .15
Hospital mortality 8 (13.1) 6 (10.5) .66
90-day mortalityc 17 (27.9) 13 (22.8) .41
NOTE. Analyses were performed on an intention-to-treat basis.
ACLF, acute-on-chronic liver failure.
aIn the albumin-plus-antibiotics group there was 1 infection caused by extended-spectrum b-lactamase Escherichia coli. In the antibiotics-alone group, there were
3 infections caused by vancomycin-susceptible Enterococcus faecium, 3 by E coli (1 extended-spectrum b-lactamase), 2 Klebsiella pneumoniae (1 extended-
spectrum b-lactamase, 1 carbapenem-resistant), and 1 by vancomycin-resistant E faecium.
bIn these cases, ACLF developed during the next 7 days after inclusion with no new infections or other clinical events within this period.
cSeven patients were lost to follow-up at 90 days (5 in the albumin-plus-antibiotics group and 2 in the antibiotics-alone group).




















































































































928Another patient received only 20 g of albumin on Days 1
and 3. Additional data on albumin treatment are shown
in the Supplementary Material.
Primary Outcome
Death in hospital occurred in 8 patients (13.1%) in
the study group, and 6 patients (10.5%) in the controlFLA 5.6.0 DTD  YJCGH56661_proof  2group (hazard ratio in the study group, 1.2; 95% confi-
dence interval, 0.5–3.4; P ¼ .7789).Secondary Outcomes
Effectsof treatmentonchanges inbaselinedata. Albumin
concentration increased significantly only in the study
group (Table 2). However, it reached normal levels in7 September 2019  12:10 am  ce CJ




















































































































1044only 12 out of the 49 patients with hypoalbuminemia at
enrollment (Figure 1A). Patients of the study group
significantly improved kidney and circulatory function
within the first 7 days after enrollment (Table 2,
Figure 1B). These patients also developed a significant
suppression of systemic inflammation (decrease in WBC
[Figure 1C], CRP, and plasma IL6 concentrations). In
contrast, patients from the control group only experi-
enced a significant decrease in CRP. Changes in these
inflammatory parameters were, however, not significantly
different in the between-group comparison (Table 2).
Most patients received adequate empiric antibiotic
therapy (Table 2). Resolution of the baseline infection
was obtained in 107 patients (90.7%), with similar rates
between groups. Resolution of infection could not be
determined in 3 patients (2 in the study group) who
were discharged under antibiotic therapy and were lost
to follow-up. The remaining 8 patients (6.8%) suffering
from pneumonia (n ¼ 4), bacteremia (n ¼ 2), and
cellulitis and UTI (n ¼ 1, each) died before resolution of
the infection. Six patients in the study group and 2 in the
control group developed septic shock.
Most patients with ACLF at enrollment (17 out 26;
65.4%) resolved the syndrome. Resolution of ACLF was
significantly higher in the study group (82.4% vs 33.3%;
P ¼ .03; Figure 1D). Resolution of KD at enrollment was
similar in both groups (70% and 60%, respectively).
Overall, the percentage of patients who resolved ACLF or
KD in the 2 groups was 77.8% and 42.9%, respectively
(P ¼ .03).
Effects of treatment on the development of new events
during hospitalization and on 90-day survival. The me-
dian (interquartile range) duration of hospitalization was
11 (6–27) and 14 (8–27) days in the study and control
groups (P ¼ NS), respectively. Twenty patients devel-
oped 23 episodes of nosocomial bacterial infections
(Table 3). The most frequent infections were pneumonia
and bacteremia (n ¼ 5 each). The rate of newly devel-
oped bacterial infections (proven and unproven) was
significantly lower in the study group (9.8% vs 24.6%;
P ¼ .03; Table 3). The rate of newly developed proven
bacterial infections was also significantly lower (P ¼
.007) in the study group (6.6%, vs 24.6%). After
considering liver transplantation as a competing event,
the cumulative incidence of new bacterial infection was
significantly lower in the study group with a sub-
distribution hazard ratio of 0.26 (95% confidence inter-
val, 0.09–0.77) (Figure 1E).
Twelve patients in the study group and 13 in the
control group developed an episode of ACLF during
hospitalization. ACLF grades at diagnosis were similar
between groups (Table 3). The most frequent cause of
ACLF during hospitalization was bacterial infections,
either present at enrollment (n ¼ 10) or developing
during hospitalization (n ¼ 5) (Table 3).
Other significant events were variceal (n ¼ 6) and
nonvariceal (n¼ 7) hemorrhage, atrial fibrillation (n¼ 2),
and pulmonary edema (n ¼ 6). There were no significantFLA 5.6.0 DTD  YJCGH56661_proof  2between-group differences in the overall frequency of
these events (23% vs 12%; P ¼ .13). Side effects poten-
tially related with volume overload (pulmonary edema,
atrial fibrillation, and variceal bleeding) were more
frequent in the study group, although difference was not
statistically significant (16% vs 7%; P ¼ .12).
One patient in the study group and 4 in the control
group were transplanted during hospitalization, and 1
and 2 additional patients, respectively, were trans-
planted within the first 90-day period after enrollment.
Ninety-day mortality rate was 27.9% in the study and
22.8% in the control group (P ¼ .41). The cumulative
incidence of death at 90-days did not differ between
the 2 study groups, with a subdistribution hazard ratio
of 1.22 (95% confidence interval, 0.60–2.50)
(Figure 1F).
Results of the Per-Protocol Analysis
Eleven patients, 5 in the study group and 6 in the
control group, presented relevant protocol deviations
and were excluded from the per-protocol analysis. Re-
sults in the per-protocol population were similar to those
observed in the ITT population (Supplementary
Tables 5–7, Supplementary Figure 2).
Risk Factors for Relevant Events During
Hospitalization, Including Death
Factors obtained at enrollment showing significant
association with relevant events occurring during hos-
pitalization, in-hospital, and 90-day mortality are indi-
cated in Supplementary Table 8.
Discussion
The 2 RCTs so far published assessing albumin
treatment in patients with non-SBP infections7,8 were
important in the design of our trial. First, we chose
hospital mortality instead of 90-day mortality rate as the
main endpoint because most patients in these trials died
within the first 30 days. Second, because mortality rate in
these studies was low,7,8 we selected patients with a
potential high hospital mortality rate.9
The current study did not show significant differ-
ences in in-hospital and 90-day mortality rates between
treatment arms, confirming the results of the prior RCTs.
However, our trial disclosed outstanding findings that
have never been reported.
A most relevant feature, which affects the interpre-
tation of the main clinical results of the trial, was that the
combined prevalence at enrollment of 2 important pre-
dictors of mortality in patients with decompensated
cirrhosis (ACLF and KD) was significantly higher in the
study group. However, ACLF at enrollment was the most
accurate predictor of hospital and 90-day mortality in
the trial. Therefore, disease severity at enrollment was7 September 2019  12:10 am  ce CJ
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1160significantly greater in those patients assigned to the
study group. This might explain the lack of effect of al-
bumin treatment on mortality despite inducing signifi-
cant beneficial effects on important pathophysiological
mechanisms and complications.
First, we observed a potential beneficial effect of al-
bumin on systemic inflammation within the first 7 days
of treatment. Any decrease in inflammatory biomarkers
in our patients could be attributed to a rapid control of
the infection. However, whereas treatment with antibi-
otics alone was associated with a significant decrease in
CRP but not in WBC or IL6, treatment with antibiotic
plus albumin led to significant reduction in levels of
these 3 inflammatory biomarkers. Changes were, never-
theless, not significantly different in the between-group
comparison.
Second, treatment with antibiotics plus albumin but
not with antibiotics alone was associated with improve-
ment in renal and circulatory function as indicated by a
significant increase in mean arterial pressure and serum
sodium and decrease in PRC and creatinine in the study
group but not in the control group.
Third, treatment with antibiotics plus albumin was
associated with a surprisingly high-resolution rate of the
ACLF present at enrollment (82.3%), significantly higher
than that observed in the control group (33.3%). This
resolution rate is higher than that observed in the
Chronic Liver Failure Acute-on-Chronic Failure in
Cirrhosis (CANONIC) study in patients not receiving al-
bumin,1 suggesting that albumin treatment, if adminis-
tered early after diagnosis, may increase the resolution
of ACLF.
Fourth and most important beneficial effect of albu-
min treatment was that prevalence of proven bacterial
infections during hospitalization was 4-fold lower in
patients receiving albumin, suggesting a preventive effect
of albumin on nosocomial bacterial infections. In
contrast, albumin treatment did not prevent ACLF
development during hospitalization.
The beneficial effects of albumin treatment observed
in the study could be related to its dampening action on
excessive systemic proinflammatory signals. Excessive
proinflammatory response is compensated with the
activation of anti-inflammatory mediators to prevent
immunopathology, favoring secondary infections.5,12 Al-
bumin could modulate this homeostatic compensatory
reaction and therefore protect from the development of
nosocomial infections.
Our trial has several limitations. The statistical power
to detect a potential reduction in hospital mortality in
patients treated with albumin was low because only 118
patients could be enrolled into the study. Differences in
the exclusion criteria between our trial and the cohorts
included in our pilot investigation13–15 could have
contributed to overestimation of the recruitment rate
and hospital mortality. Finally, we did not obtain good
matching between groups. Inclusion of less sick patients
in the control group could explain the lower thanFLA 5.6.0 DTD  YJCGH56661_proof  2expected hospital mortality rate in this group (10.5%).
However, the strength of the study was the study design
and inclusion of clinically important endpoints, including
the clinical effects of albumin treatment on patients’
clinical course during hospitalization.
As expected, albumin treatment significantly
increased serum albumin concentration but only a
minority of patients with hypoalbuminemia normalized
albumin concentration. The inhibition of the hepatic
synthesis of albumin by bacterial infection may ac-
count for this feature. In addition, the half-life of
circulating albumin is markedly reduced when, as it
occurs in cirrhosis, there is impairment in the molec-
ular structure of the protein.16 We have observed that
the immunomodulatory effect of albumin is highly
dependent on the post-treatment serum albumin con-
centration.17 Therefore, current albumin dosage in
patients with cirrhosis with bacterial infections may be
too simplistic. A more rational approach may consist of
the administration of a priming dose followed by
additional periodical doses tailored by the serum al-
bumin concentration.
Finally, the frequency of pulmonary edema was
slightly higher in patients receiving albumin. When all
events potentially related to volume overload were
considered together, there was a trend toward a higher
rate of these side effects in the albumin group.
In summary, in this trial involving patients with
advanced cirrhosis and infections unrelated to SBP, in-
hospital mortality was not different among patients
who received albumin plus antibiotics and those who
received antibiotics only. This occurred despite the
beneficial effects of albumin treatment on circulatory and
renal dysfunction, resolution of baseline ACLF, and pre-
vention of nosocomial infections. Disease severity at in-
clusion, however, was greater in the group of patients
treated with albumin. Further appropriately designed
and powered RCTs are needed to ascertain if albumin
treatment decreases mortality in patients with cirrhosis
with non-SBP bacterial infections.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2019.07.055.7 SepReferences
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Exclusion Criteria. Exclusion criteria were infections
evolving for >72 hours, septic shock,1 endocarditis,
fungal infection, severe acute respiratory distress syn-
drome (PaO2/FIO2 100), active or recent variceal
bleeding (unless controlled for >48 hours), type-1 HRS
(International Ascites Club criteria),2 ACLF grade-3 (3 or
more organ failures [OFs] according to the Canonic Study
criteria),3 renal-replacement therapy, malignancy
(except for hepatocellular carcinoma within Milan
criteria or nonmelanocytic skin cancer), moderate or
severe chronic heart failure (New York Heart Association
functional class II, III, or IV), severe chronic pulmonary
disease (Global Initiative for Chronic Obstructive Lung
Disease IV), previous liver transplantation, severe psy-
chiatric disorders that prevent the patient from making
autonomous decisions, human immunodeficiency virus
infection (except for patients under antiretroviral ther-
apy with undetectable viral load, CD4 levels >200/mm3,
and no previous history of opportunistic infections),
contraindications to albumin (allergy, signs of pulmonary
edema), albumin administration (80 g) in the last 2
days, SBP coinfection, administration of any investiga-
tional drug within 90 days before randomization, pre-
menopausal women not practicing an acceptable method
of birth control, refusal to participate, patients who could
not provide prior informed consent and when there was
documented evidence that the patient had no legal sur-
rogate decision maker and it seemed unlikely that the
patient would regain consciousness or sufficient ability
to provide delayed informed consent, and physician and























Acute-on-chronic liver failure. The diagnosis of ACLF
and its grades were performed according to the Canonic
study criteria.3 ACLF was defined as the association of
acute decompensation (defined as ascites, encephalopa-
thy, variceal hemorrhage, or any combination of these),
single or multiple (2) OFs, and high short-term (28-
day) mortality risk (>15%). OF was defined for each of
the 3 major organ systems (liver, kidney, brain, coagu-
lation, circulation, and respiration) as a CLIF-Consortium
OF score of 2 or 3 (on a scale ranging from 1 to 3 for each
organ system)3 (Supplementary Table 1). In brief, for
nonkidney organ systems, a score of 1 indicated normal
of relatively preserved organ function; a score of 2, organ
dysfunction (OD), including liver dysfunction, brain
dysfunction, coagulation dysfunction, circulatory
dysfunction, and respiratory dysfunction); and a score of
3, OF. For the kidney, scores of 2 and 3 indicated kidney
failure. Among patients with a kidney score of 1, thoseFLA 5.6.0 DTD  YJCGH56661_proof  2who had serum creatinine levels ranging from 1.5–1.9
mg/dL were defined as having KD.
According to Canonic criteria, patients with acute
decompensation are classified into 4 groups according to
the number and type of OFs 1 (Supplementary Table 2):
1. ACLF-3: 3–6 OFs (mortality risk, 75%)
2. ACLF-2: 2 OFs (mortality risk, 32%)
3. ACLF-1: Single kidney failure, or single nonkidney
OF if associated with KD and/or brain dysfunction
(mortality risk, 22%)
4. No ACLF: None of these characteristics (mortality
risk, 4.6%). Please note that patients from this
group may have single nonkidney OF
(Supplementary Table 1) or single or combined
OD.
Resolution of ACLF was defined as a decrease from
any grade of ACLF to no ACLF.4
Bacterial infections. Definitions and diagnostic
criteria of infections were the following. SBP: poly-
morphonuclear (PMN) cell count in ascitic fluid 250/
mm3; UTI: abnormal urinary sediment (>10 leukocytes/
field) or a positive reagent strip and positive urinary
culture or uncountable leukocytes per field if negative
cultures; spontaneous bacteremia: positive blood cul-
tures and no cause of bacteremia; secondary bacteremia:
catheter-related infection (positive blood and catheter
cultures), and bacteremia occurring within 24 hours af-
ter an invasive procedure; pneumonia: clinical signs of
infection and new infiltrates on chest radiograph; bron-
chitis: clinical features of infection, no radiographic in-
filtrates, and positive sputum culture; cellulitis: clinical
signs of infection associated with swelling, erythema,
heat, and tenderness in the skin; cholangitis: cholestasis,
right upper quadrant pain and/or jaundice, and radio-
logic data of biliary obstruction; spontaneous bacterial
empyema: PMN count in pleural fluid 500/mm3 (250/
mm3 if positive culture); secondary peritonitis: PMN
count in ascitic fluid 250/mm3 and evidence (abdom-
inal computed tomography/surgery) of an intra-
abdominal source of infection; Clostridium difficile
infection: positive stool toxin in a patient with diarrhea;
unproved bacterial infection: presence of fever (38C)
and leukocytosis (white blood cell count 12.000/mm3)
requiring antibiotic therapy without any identifiable
source. Infections diagnosed at admission or within 2
days after admission were classified as health
care–associated (HCA) in patients with a prior contact
with the health care environment (hospitalization or
short-term admission for at least 2 days in the previous
90 days, residence in a nursing home or a long-term care
facility, or chronic hemodialysis). The remaining in-
fections were considered community-acquired (CA)
when they were present at admission or developed
within the first 48 hours after hospitalization and noso-
comial when the diagnosis was made thereafter.57 September 2019  12:10 am  ce CJ
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1501MDR was defined as acquired nonsusceptibility to at
least 1 agent in 3 or more antimicrobial categories.6 The
following bacteria were considered MDR in the current
study: extended-spectrum b-lactamase (mainly Escher-
ichia coli and Klebsiella pneumoniae) or desrepressed
chromosomic AmpC ß-lactamase-producing Enterobac-
teriaceae (Enterobacter, Citrobacter, and Proteus spp),
carbapenem-resistant K pneumoniae, carbapenem-
resistant Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, carbapenem-resistant Acinetobacter bauma-
nii, methicillin-resistant Staphylococcus aureus (MRSA),
and vancomycin-susceptible Enterococcus faecium.
Patientswere considered tohave systemic inflammatory
response syndrome (sepsis) if they fulfilled at least 2 of the
following criteria: (1) core temperature >38C or <36C;
(2) heart rate >90 beats/minute; (3) respiratory rate >20
breaths/minute in the absence of hepatic encephalopathy;
and (4) white blood cell count>12.000 or<4000 /mm3, or
differential count showing 10% immature PMN neutro-
phils. Septic shock was diagnosed by the presence of data
compatiblewith systemic inflammatory response syndrome
and need of vasopressor drugs in the setting of hypoten-
sion.1 Recently defined sepsis criteria were not applied in
the current study because theywere proposed after the end
of the Canonic Study.
Infections were considered cured when all clinical
signs of infection disappeared and on the presence of: (1)
urinary infections: normal urine sediment and negative
urine culture; (2) spontaneous or secondary bacteremia:
negative control cultures after antibiotic treatment; (3)
pneumonia: normal chest radiograph and negative con-
trol cultures if positive at diagnosis; (4) bronchitis:
negative bronchial aspirate/sputum culture; (5) cellu-
litis: normal physical examination of the skin and nega-
tive control cultures if positive at diagnosis; (6)
cholangitis: improvement of cholestasis, resolution of
clinical symptoms, and negative control cultures if posi-
tive at diagnosis; and (7) SBP and spontaneous bacterial
empyema: PMN cell count in ascitic/pleural fluid <250/
mm3 and negative control cultures if positive at diag-
nosis. Resolution of the rest of infections was based on
conventional clinical criteria.5
The criteria used to consider an initial antibiotic
therapy appropriate were the following: culture-positive
infections, if an antibiotic with an in vitro activity
appropriate for the isolated pathogen or pathogens was
administered at diagnosis of infection; and culture-
negative infections, when the antibiotic strategies
administered at the time of infection diagnosis solved the
infection without need for further escalation. Otherwise,






1508Empirical Antibiotic Treatment Suggested in the
Study
Empirical antibiotic treatment should be adminis-
tered within the first 6 hours after infection diagnosisFLA 5.6.0 DTD  YJCGH56661_proof  2and will be different for infections acquired in the com-
munity (CA infections) and HCA or nosocomial infection
because of the higher prevalence of multiresistant bac-
teria in the later infections. Treatment schedule will be
adapted to the local epidemiologic pattern of multi-
resistance. The suggested empirical treatment in this
protocol as follows.
Community-acquired infections. CA infections will
be treated as follows: ceftriaxone for urinary and sus-
pected bacterial infection; ceftriaxone plus cloxacillin or
amoxicillin clavulanic-acid for cellulitis; piperacillin-
tazobactam for cholangitis; and ceftriaxone and a
macrolide or levofloxacin in patients with pneumonia.
Ceftriaxone plus clindamycin will be administered in
case of aspiration pneumonia.
Health care–associated and nosocomial infec-
tions. Empirical antibiotic regimen in HCA or nosocomial
infections will be the following: carbapenem for urinary
and suspected bacterial infection (plus a glycopeptide in
areas with a high prevalence of E faecium); imipenem for
cholangitis (plus a glycopeptide in areas with a high
prevalence of E faecium); antipseudomonic carbapenem
(meropenem, imipenem, or doripenem) or ceftazidime
plus glycopeptide for cellulitis; and antipseudomonic
carbapenem or ceftazidime plus ciprofloxacin in patients
with pneumonia. Vancomycin, teicoplanin, or linezolid
will be added in patients with pneumonia and risk fac-
tors for MRSA (ventilator-associated pneumonia, previ-
ous antibiotic therapy, nasal MRSA carriage).
Antibiotics will be administered intravenously at
standard doses: ceftriaxone, 2 g at diagnosis followed by
1 g/12–24 hours; amoxicillin clavulanic-acid, 2–0.4 g/8
hours; cloxacillin, 2 g/6 hours; clarithromycin, 500 mg/
12 hours; levofloxacin, 500 mg/12–24 hours; clindamy-
cin, 600 mg/8 hours; piperacillin-tazobactam, 4 g/6–8
hours; meropenem, 1 g/8 hours; doripenem, 0.5 g/8
hours; imipenem, 0.5–1 g/6–8 hours; ertapenem, 1 g/
12–24 hours; ceftazidime, 2 g/8 hours; ciprofloxacin, 400
mg/8–12 hours; vancomycin, 15–20 mg/kg/8–12 hours;
teicoplanin, 6 mg/kg; and linezolid, 600 mg/12 hours.
Doses will be adjusted to renal function (glomerular
filtration rate will be estimated by the Cockcroft-Gault or
the MDRD equations following local guidelines). De-
escalation to the most appropriate antibiotic should be
done early after knowing the results of the microbiologic
tests.
Antibiotic treatment will be maintained until the
disappearance of signs and symptoms of infection,
normalization of the white blood cell count, and
negative cultures. Patients with positive cultures at
infection diagnosis will have to have control negative
cultures before stopping antibiotics. Suggested dura-
tion of treatment in CA infections will be of 7 days
except for pyelonephritis, cholangitis, and cellulitis (10
days). Suggested duration of treatment in HCA and
nosocomial infections will be of 10 days, except for
pneumonia and cellulitis caused by multiresistant
bacteria (14 days).7 September 2019  12:10 am  ce CJ




















































































































1624Assessment of Disease Severity at Enrollment
To avoid the limitations of the previous trials
regarding patients’ severity, only cases with acute
decompensation and significant liver and renal impair-
ment, as prespecified by high levels of serum bilirubin
and/or creatinine and/or low plasma sodium levels,
were enrolled in our trial. Patient severity at enrollment
was initially planned to be assessed by these measure-
ments and by the Model for End-Stage Liver Disease and
Child-Pugh scores. However, investigations published
between the study design and data analysis7-10 showed
important limitations of these measurements and scores.
Moreover, the diagnostic criteria of ACLF proposed by
the Canonic study leave many patients with single non-
kidney OF or with single or combined OD in the non-
ACLF group (Supplementary Tables 1 and 2). Recent
data indicate that these patients are at higher risk of
developing worse clinical course or dying than those
without OF or OD.11 However, KD was found to be an
accurate marker of high short-term mortality (19.2% vs
5.7% in patients with and without KD, respectively; P ¼
.02) in a pilot investigation in 496 patients without ACLF
from Canonic study database (Supplementary Table 3).
Based on these results, we decided to add ACLF and KD
at enrollment as indicators of disease severity before
data analysis.
Results
Microbiology of Bacterial Infections Diagnosed
at Inclusion
E coli was the most frequently isolated organism
(34.8%), followed by S aureus (14.5%); K pneumoniae
(10.1%); and Streptococcus viridans, Enterobacter spp,
and Enterococcus faecalis (4.3% each). Twenty-six of the
69 organisms isolated in the study (37.7%) were
multidrug-resistant organisms. They were isolated in 24
infections (20.3% of all infections, 38.1% of culture-
positive infections). As a whole, extended-spectrum b-
lactamase-producing E coli was the most frequent
multidrug-resistant organism reported (n ¼ 9), followed
by MRSA (n ¼ 4) (Supplementary Table 4).
Albumin Administration
Albumin treatment was initiated after the first 8
hours following randomization in 4 patients. Overall, the
median albumin doses (interquartile range [IQR])
administered on Day 1 and Day 3 were 100 (90–110 g)
and 62.5 (60–80 g), respectively. The median difference
(IQR) between the scheduled dose and the administered
dose of albumin on Day 1 was 0 (-2.5 to 0.5 g) and 0 (0–1
g) on Day 3. Nine patients (6 in the control group and 3
in the study group) received relevant albumin doses (1
g/kg body weight) within the first week afterFLA 5.6.0 DTD  YJCGH56661_proof  2randomization for the treatment of complications other
than the initial infection. The median albumin doses
(IQR) administered were 80 (70–100 g) in the study
group and 60 (55–90 g) in the control group,
respectively.
Risk Factors for Relevant Events During
Hospitalization, Including Death
Factors obtained at enrollment showing significant
association with relevant events occurring during hos-
pitalization, in-hospital, and 90-day mortality are indi-
cated in Supplementary Table 8. Albumin treatment was
independently associated with lower prevalence of
proven bacterial infections. Diabetes was independently
related to the development of pulmonary edema. Hepatic
encephalopathy and severity of systemic inflammation
(as estimated by WBC) at enrollment were indepen-
dently associated with a higher prevalence of ACLF.
Finally, ACLF at enrollment was the only independent
predictor of in-hospital mortality, the primary outcome
of the trial, and was also identified as an independent
predictor of 90-day mortality together with bacteremia
and prothrombin index.
Baseline serum albumin levels were lower in patients
included in the study group who developed ACLF or
bacterial infections during hospitalization, although dif-
ferences were not statistically significant
(Supplementary Table 9).
Supplementary Table 10 shows details concerning
the main events occurring during hospitalization in pa-
tients who died and their causes of death. Death was
related with lack of resolution of bacterial infections in
11 patients (8 corresponding to infections detected at
enrollment).7 SepReferences
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Figure 1. Flow chart of the
study. Overall, 534Q19 patients
were assessed for eligi-
bility, and 433 subjects
were excluded. A total of
136 patients were enrolled.
Eighteen patients were
considered inclusion er-
rors. The final ITT popula-
tion consisted of 118
patients, 61 in the study
group and 57 in the control
group. Eleven patients, 5 in
the study group and 6 in
the control group, pre-
sented relevant protocol
deviations. Seven patients
were lost to follow-up at 90
days. ARDS, acute respi-
ratory distress syndrome;
GOLD, Global Initiative for
Chronic Obstructive Lung
Disease; HCC, hepatocel-
lular carcinoma; HIV, hu-
man immunodeficiency
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Supplementary Figure 2. Cumulative incidence of death by
90 days in the per-protocol population, when liver trans-
plantation was taken into account as a competing risk of
death. At 90 days, the estimated cumulative incidence of
death was 28.9% (95% confidence interval, 17.2%–41.7%) in
the albumin-plus-antibiotics group and 21.3% (95% confi-
dence interval, 10.9%–34.1%) in the antibiotics-alone group.
No significant differences were observed between groups.
ALB-G, ---; SMT-G, ---Q14 .
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Supplementary Table 1. Diagnostic Criteria of Organ Failures and Organ Dysfunctions According to the CLIF-Consortium
Organ Failure Scoring System
Organ system
Scale assessing the deterioration in organ system functions
1 point 2 points 3 points
Liver Bilirubin <6 mg/dL Bilirubin 6 mg/dL and 12 mg/dL Bilirubin >12 mg/dL
Kidney Creatinine <2 mg/dL Creatinine 2 mg/dL and <3.5 mg/dL Creatinine 3.5 mg/dL or RRT
Creatinine from 1.5 to 1.9 mg/dL
Brain (West-Haven) Grade 0 Grade 1–2 Grade 3–4
Coagulation INR <2.0 2.0  INR <2.5 INR 2.5









NOTE. Adapted from Reference 3. Each organ system (liver, kidney, coagulation, brain, circulation, respiration) receives a score ranging from 1 point (normal or
close to normal) to 3 points (most abnormal). Highlighted areas in blue reflect the definition of each organ failure. Highlighted areas in orange reflect the definition of
each organ dysfunction. The sum of the 6 individual organ scores gives rise to an aggregated score called CLIF-Consortium organ failure score, ranging from 5 to
15, higher scores indicating more severe disease.
CLIF, chronic liver failure; FIO2, fraction of inspired oxygen; INR, international normalized ratio; MAP, mean arterial pressure; RRT, renal-replacement therapy;
SpO2, pulse oximetric saturation.
aPatients treated with mechanical ventilation received a respiratory organ failure score of 3 points.
Supplementary Table 2.Mortality Rates by 28 Days According to the Number and Types of In-Patients With or Without
Kidney and/or Brain Dysfunction (Canonic Study)
Number and types of OF
No kidney dysfunction and
no brain dysfunction
Kidney dysfunction or brain
dysfunction, or both
Mortality rate (%)
OF absent 3.6 6.2
Single liver failure 5.9 30.3
Single cerebral failure 8.0 20.0
Single coagulation failure 5.3 22.2
Single circulation or single
respiratory failure
6.7 28.6
Single kidney failure 15.8 24.1
Two OFs 28.8 38.7
Three OFs or more 86.2 61.5
NOTE. Adapted from Reference 1 (main manuscript). The highlighted colored areas show the subgroups of patients with ACLF: in blue ACLF-1, in orange ACLF-2,
in yellow ACLF-3.
ACLF, acute-on-chronic liver failure; OF, organ failure.
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Supplementary Table 3. Development of ACLF and Death by 28 Days Among the 496 Patients Without ACLF but With




by 28 d P value 28-d mortality P value
Liver, n/N (%)
Liver dysfunction or liver failure only 12/54 (22.2) .003 4/52 (7.7) .076
No liver dysfunction or liver failurea 50/442 (11.3) 27/427 (6.3)
Kidney, n/N (%)
Kidney dysfunction only 12/28 (42.9) < .00001 5/26 (19.2) .002
No kidney dysfunctiona 50/468 (10.7) 26/453 (5.7)
Brain, n/N (%)
Brain dysfunction or failure only 6/85 (7.1) .01 3/83 (3.6) .033
No brain dysfunction or brain failurea 56/411 (13.6) 28/396 (7.1)
Coagulation, n/N (%)
Coagulation dysfunction or failure only 1/11 (9.1) 1.0 2/11 (18.2) .015
No coagulation dysfunction or coagulation failurea 61/485 (12.6) 29/468 (6.2)
NOTE. Among the 496 patients, 62 developed ACLF and 31 died by 28 days.
ACLF, acute-on-chronic liver failure.
aIncludes patients with or without other organ dysfunction.
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(n ¼ 57) Total
Number of isolated bacteria, n 35 34 69
Number of gram-negative bacteria 23 19 42
Number of each isolate
Escherichia coli 13 11 24
ESBL 5 4
Carbapenem-resistant 1
Klebsiella pneumoniae 4 3 7
ESBL 1
Carbapenem-resistant 1
Klebsiella oxytoca 1 1
Enterobacter spp 3 3
Citrobacter spp 1 1 2
Proteus spp 1 1




Acinetobacter baumanii 1 1
Bacteroides fragilis 1 1
Number of gram-positive cocci 10 13 23
Number of each isolate
Enterococcus faecalis 2 1 3
Staphylococcus aureus 4 6 10
Methicillin-sensitive S aureus 2 4
Methicillin-resistant S aureus 2 2
Enterococcus faecium (VSE) 1 1
Streptococcus pneumoniae 1 1
Streptococcus viridans 3 3
Streptococcus agalactiae 2 2
Streptococcus oralis 1 1 2
Other GPC 1 1
Number of other organisms (n) 2 2 4
Haemophilus influenza — 2 2
Clostridium difficile 2 — 2
ESBL, extended-spectrum b-lactamase; GPC, ---; VSE, vancomycin-susceptible Enterococcus Q15.
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(n ¼ 51) P value
Demographic, clinical, and laboratory data
Age, y 58.5  13.9 57.6  10.7 .071
Male sex, n (%) 34 (60.7) 33 (64.7) .067
Alcoholic cirrhosis, n (%) 28 (50.0) 36 (70.6) .003
Diabetes mellitus, n (%) 18 (32.1) 17 (33.3) .090
Ascites, n (%) 44 (78.6) 38 (74.5) .062
Mean arterial pressure, mm Hg 77.5  11.4 79.1  10.7 .046
Median value (interquartile range) for
serum bilirubin, mg/dL
4.3 (1.8–7.0) 4.6 (2.0–11.0) .051
Serum albumin, g/L 26.1  6.6 26.4  5.8 .085
Prothrombin ratio, n (%) 49.8 (12.7) 48.5  16.3 .071
Serum creatinine, mg/dL 1.3  0.7 1.1 (0.4) .006
Serum sodium, mEq/L 131.6 (6.3) 132.4 (5.4) .051
Serum bilirubin 4 mg/dL, n (%) 31 (56.4) 30 (58.8) .080
Serum creatinine 1.2 mg/dL, n (%) 31 (56.4) 24 (47.1) .034
Serum sodium <130 mEq/L, n (%) 30 (53.6) 25 (49.0) .064
Serum creatinine 1.2 mg/dL or serum
sodium <130 mEq/L, n (%)
45 (80.4) 39 (76.5) .063
Median values (interquartile range) for markers
of inflammation and circulatory dysfunction
White blood cell count, x109/L 7.1 (4.8–11.5) 7.7 (4.4–11.7) .090
Serum C-reactive protein, mg/dL 11.9 (4.8–48.0) 15.0 (4.1–34.2) .091
Plasma interleukin 6, pg/mL 38 (22–159) 38 (18–71) .059
Plasma renin concentration, mIU/mL 242 (46–903) 93 (26–327) .018
Presence of ACLF or kidney dysfunction, n (%)
ACLF-1 11 (19.6) 6 (11.8) .069
ACLF-2 3 (5.4) 1 (1.9)
ACLF 14 (25.0) 7 (13.7) .014
Kidney dysfunction 10 (17.9) 5 (9.8) .023
ACLF or kidney dysfunction 24 (42.8) 12 (23.5) .003
Liver scores
Child-Pugh score, points 10.3  2.1 10.4  1.9 .076
Model of End-Stage Liver Disease score, points 19.5  5.6 19.4  5.1 .095
CLIF-C OF score, points 7.3  1.6 7.5  1.7 .063
Site and severity of infection, n (%)
Pneumonia 14 (25.0) 20 (39.2) .011
Urinary tract infection 15 (26.8) 10 (19.6) .038
Spontaneous or secondary bacteremia 11 (19.6) 8 (15.7) .059
Cellulitis 2 (3.6) 5 (9.8) .019
Cholangitis 3 (5.4) 0 .024
Unproven infections 9 (16.1) 8 (15.7) .096
Other 2 (3.6) 0 .050
Presence of sepsis, n (%) 32 (57.1) 25 (49.0) .040
Site of acquisition of infection, n (%)
Community-acquired 16 (28.6) 14 (27.5) .095
Health care–associated 36 (64.3) 34 (66.7)
Nosocomial 4 (7.1) 3 (5.9)
Results of microbial culture, n (%)
Culture-positive 31 (55.4) 29 (56.9) .088
Presence of multidrug-resistant bacteria 10 (17.9) 14 (27.5) .024
NOTE. Plus–minus values are means  standard deviation.
ACLF, acute-on-chronic liver failure; CLIF-C OF, CLIF-Consortium organ failure score.
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Supplementary Table 6. Effects of Treatment on Standard Laboratory Tests, Biomarkers of Systemic Inflammation and
Circulatory Dysfunction, and on the Course of Bacterial Infection and ACLF Diagnosed at Enrollment
















Serum albumin and liver, kidney,
and circulatory function
Serum albumin, g/L
Baseline 23.6 (9.5) 24.4 (8.7)
Day 3–7 30.6 (10.01) < .00001 24.5 (8.3) .01809 < .00001
Median value for serum bilirubin
(IQR), mg/dL
Baseline 4.3 (1.8–7.0) 4.6 (2.0–11.0)
Day 3–7 4.0 (2.3–7.5) .07429 4.0 (1.3–9.7) .00174 .02033
Prothrombin ratio, %
Baseline 49.8 (12.7) 48.5 (16.3)
Day 3–7 48.6 (14.4) .02785 49.1 (14.8) .06432 .02683
Serum creatinine, mg/dL
Baseline 1.3 (0.07) 1.1 (0.04)
Day 3–7 1.1 (0.06) .00136 1.0 (0.04) .00821 .02788
Serum sodium, mEq/L
Baseline 131.6 (6.3) 132.4 (5.4)
Day 3–7 134.7 (5.4) < .00001 133.3 (4.8) .00762 .00130
Mean arterial pressure, mm Hg
Baseline 77.5 (11.4) 79.1 (10.07)
Day 3–7 82.1 (12.1) .00050 8 .09 (10.05) .02305 .01966
Median value for plasma renin
concentration, (IQR), micro IU/mLd
Baseline 242 (46.903) 93 (26–327)
Day 3–7 161 (18–393) .00002 65 (24–480) .05386 .00040
Median value for markers of
inflammation (IQR)
White blood cell count, x109/L
Baseline 7.1 (4.8–11.5) 7.7 (4.4–11.7)
Day 3–7 5.8 (4.0–9.0) .00008 6.2 (4.2–9.4) .00272 .03778
Serum C-reactive protein, mg/dL
Baseline 11.9 (4.8–48.0) 15.0 (4.1–34.2)
Day 3–7 8.7 (3.8–28.0) < .00001 8.6 (3.8–31.0) < .00001 .08927
Plasma interleukin 6, pg/mLe
Baseline 38 (22–159) 38 (18–71)
Day 3–7 32 (18–71) .00194 28 (13–59) .01176 .08153
Course of infection, n (%)
Adequate empirical antibiotics 50 (89.3) 45 (88.2) .0864
Septic shock 3 (5.4) 1 (2.0) .068
Infection resolution 50 (89.3) 49 (96.1) .038
Course of ACLF or kidney dysfunction, n/N (%)
Resolution of ACLFf 11 (78.6) 2 (28.6) .006
Resolution of kidney dysfunction 7 (70.00) 3 (60.00) .024
Resolution of ACLF or kidney dysfunction 18 (75.0) 5 (41.7) .004
NOTE. Plus–minus values are means  standard deviation.
ACLF, acute-on-chronic liver failure; IQR, interquartile range.
aComparison of baseline vs Day 3–7, in the albumin-plus-antibiotics group.
bComparison of baseline vs Day 3–7, in the antibiotics-alone group.
cBetween-group comparison was performed at Day 3–7.
dPlasma renin concentrations were determined at Day 1, and Day 3–7 in 40 patients in the albumin-plus-antibiotics group and in 37 patients in the antibiotics-alone
group.
eInterleukin 6 levels were determined at Day 1, and Day 3–7 in 47 patients in the albumin-plus-antibiotics group and in 43 patients in the antibiotics-alone group.
fThe 3 patients with ACLF-2 in the albumin-plus-antibiotics group solved the syndrome; this did not occur in the single patient with ACLF-2 of the antibiotics-alone
group.
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Supplementary Table 7. New Events During Hospitalization and Short-Term Mortality in the Per-Protocol Population
Event
Albumin plus
antibiotics (n ¼ 56)
Antibiotics
alone (n ¼ 51) P value
New bacterial infections
Patients with infections, n (%)
Patients with proven or unproven infections 5 (8.9) 11 (21.6) .007
Patients with proven infections 4 (7.1) 11 (21.6) .003
Type and severity of infections, n (%) 6 13
Pneumonia .030
Spontaneous or secondary bacteremia 1 (1.8) 3 (5.9)
Urinary tract infection 1 (1.8) 4 (7.8)
Spontaneous bacterial peritonitis 1 (1.8) 3 (5.9)
Cellulitis 1 (1.8) 0
Unproven infections 1 (1.8) 0
Clostridium difficile infection 1 (1.8) 0
Other 0 2 (3.9)
Number of infectious episodes 4 (7.1) 3 (5.9) .079
Presence of sepsis 0 1 (1.9)
Microbiology and course of infection, n (% of infections)
Culture positivea 1 (16.7) 9 (69.2) .006
Multidrug-resistant bacteria 1 (14.3) 6 (46.2) .033
Adequate empirical antibiotics 4 (66.7) 11 (84.6) .056
Septic shock 2 (33.3) 3 (23.1) .064
Infection resolution 4 (66.7) 10 (76.9) .064
New episodes of ACLF, n (%)
Patients with ACLF, n (%)
ACLF-1 6 (10.7) 4 (7.8) .029
ACLF-2 4 (7.1) 3 (5.9)
ACLF-3 0 2 (3.9)
Overall ACLF 10 (17.9) 9 (17.6) .098
Potential mechanisms of the new ACLF, n (%) .060
Recurrence of a resolved ACLF 1 (1.8) 0
Precipitated by baseline bacterial infectionb 4 (7.1) 5 (9.8)
Precipitated by new bacterial infection 1 (1.8) 1 (1.9)
Unknown mechanism 4 (7.1) 3 (5.8)
Course of ACLF, n (%)
Resolution 3 (5.4) 3 (5.9) .049
Other clinical events, n (%)
Variceal bleeding 4 (7.1) 2 (3.9) .047
Nonvariceal bleeding 4 (7.1) 2 (3.9) .047
Atrial fibrillation 2 (3.6) 0 .050
Pulmonary edema 1 (1.8) 2 (3.9) .032
Liver transplantation and mortality, n (%)
Liver transplantation during hospitalization 1 (1.8) 4 (7.8) .019
Liver transplantation by 90 d 2 (3.6) 6 (11.8) .015
Hospital mortality 6 (10.7) 5 (9.8) .088
90-d mortalityc 15 (26.8) 10 (19.6) .016
NOTE. Categorical variables as number and percentage or number.
ACLF, acute-on-chronic liver failure; ESBL, extended-spectrum b-lactamase.
aIn the albumin-plus-antibiotics group there was 1 infection caused by ESBL Escherichia coli. In the antibiotics-alone group there were 3 infections caused by
vancomycin-susceptible Enterococcus faecium, 2 by E coli (1 ESBL), 1 by carbapenem-resistant Klebsiella pneumoniae, and 1 by vancomycin-resistant E faecium.
bIn these cases, ACLF developed during the next 7 days after inclusion with no new infections or other clinical events within this period.
cSix patients were lost to follow-up at 90 days (5 in the albumin-plus-antibiotics group and 1 in the antibiotics-alone group).
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Supplementary Table 8. Analysis of Risk Factors at Inclusion for the Development of New Bacterial Infections, New ACLF,
Pulmonary Edema, and Short-Term Mortality
Variable Event absent Event present P value Odds ratio
95% confidence
interval P value
New proven bacterial infections
Treatment with albumin, n/N (%) 57/100 (57.0) 4/18 (22.2) .0007 0.22 0.07–0.70 .001
New ACLF
Hepatic encephalopathy, n/N (%) 39/93 (41.9) 16/25 (64.0) .005 18.51 1.20–286.59 .004




6.7 (4.2–11.7) 9.2 (6.5–10.0) .002 1.22 1.01–1.47 .004
Median value for serum bilirubin,
mg/dL (IQR)
4.3 (1.7–7.2) 6.6 (4.3–11.8) .002
Median value for plasma renin
concentration, mIU/mL (IQR)
133 (28–385) 604 (149–1316) .001
Pulmonary edema
Diabetes mellitus, n/N (%) 33/112 (29.5) 5/6 (83.3) .001 12.17 1.36–108.56 .003
Serum albumin, g/L 24.1 (8.9) 21.2 (1.4) .0007
Hospital mortality
Hepatic encephalopathy, n/N (%) 45/104 (43.3) 10/14 (71.4) .005
ACLF at enrollment, n/N (%) 18/104 (17.3) 8/14 (57.1) < .0001 17.63 1.63–191.21 .002
ACLF or kidney dysfunction at
enrollment, n/N (%)
31/104 (29.8) 10/14 (71.4) .0005
Median value for serum bilirubin,
mg/dL (IQR)
4.4 (1.8–7.4) 7.8 (5.5–16.7) .0004
Prothrombin ratio, % 50.9 (14.7) 37.8 (8.7) .0005
Median value for plasma renin
concentration, mIU/mL (IQR)
160 (34–589) 1829 (660–4124) .002
90-d mortality, n/N (%)
Hepatic encephalopathy 33/81 (40.7) 19/30 (63.3) .003
ACLF at study inclusion 13/81 (16.1) 11/30 (36.7) .002 19.64 3.48–110.99 .0001
ACLF or kidney dysfunction at
enrollment
23/81 (28.4) 16/30 (53.3) .002
Spontaneous or secondary
bacteremia at inclusion
13/81 (16.1) 11/30 (36.7) .002 21.33 3.74–121.66 .0001
Median value for serum bilirubin,
mg/dL (IQR)
4.4 (1.8–7.4) 7.8 (5.5–16.7) .004
Prothrombin ratio, % 50.3 (14.1) 40.9 (10.5) .007 0.94 0.89–0.996 .004
ACLF, acute-on-chronic liver failure; IQR, interquartile range.
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Supplementary Table 9. Correlation Between Baseline
Serum Albumin Levels and the
Response to Albumin Treatment in
Patients Included in the Albumin-
Plus-Antibiotics Group
Baseline serum
albumin level, g/L P value
Resolution of baseline ACLF
No 26.9 (5.8)
Yes 25.6 (7.5) .06527
ACLF onset during hospitalization
No 26.2 (5.4)
Yes 24.9 (7.2) .03697
Onset of new bacterial infections
No 26.3 (6.1)
Yes 24.1 (5.6) .01481
Correlation with changes from
baseline mean arterial pressure
At 3 d -0.036 .07152
At 7 d 0.160 .02992
At 3/7 d -0.019 .08469
Correlation with changes from
baseline interleukin 6
At 3 d 0.043 .06932
At 7 d -0.015 .09272
At 3/7 d 0.025 .08126
ACLF, acute-on-chronic liver failure.
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enrollment Cause of death
Antibiotics-alone group (n ¼ 6)
1(02-08) Yes No Yes No No/NA/NA No/NA ACLF-3 Day 13 Multiorgan failure; no
identifiable trigger
2(03-08) No Yes No — Yes/Day 12/No Yes/Day 7 ACLF-3 Day 26 Pulmonary edema
3(14-01) No Yes Yes No No/NA/NA No/NA ACLF-3 Day 28 Multiorgan failure; no
identifiable trigger
4(17-02) Yes Yes Yes Yes Yes/Day 3/Yes
Yes/Day 50/No
Yes/Day 55 ACLF-3 Day 56 Septic shock
5 (21-03) Yes Yes No — No/NA/NA Yes/Day 21 ACLF-3 Day 22 Multiorgan failure; no
identifiable trigger
6 (24-13) Yes No Yes No No/NA/NA No/NA ACLF-3 Day 13 Septic shock
Albumin-plus-antibiotics group (n ¼ 8)
1(02-07) Yes Yes Yes Yes Yes/Day 9/Yes
Yes/Day 21/No
Yes/Day 10 ACLF-3 Day 22 Hypovolemic shock;
variceal hemorrhage
2(06-01) No No Yes No No/NA/NA No/NA ACLF-3 Day 5 Septic shock
3(09-08) Yes Yes Yes Yes No Yes/Day 28 ACLF-3 Day 31 Multiorgan failure without
identifiable trigger
4 (12-02) Yes No No — No/NA/NA Yes/Day 3 ACLF-3 Day 8 Multiorgan failure without
identifiable trigger
5 (14-15) Yes No Yes Yes No/NA/NA Yes/Day 12 ACLF-3 Day 12 Multiorgan failure without
identifiable trigger
6 (17-08) No No No — No/NA/NA Yes/Day 3 ACLF-3 Day 6 Multiorgan failure without
identifiable trigger
7(23-02) Yes No No — No/NA/NA Yes/Day 3 ACLF-2 Day 7 Multiorgan failure without
identifiable trigger
8(24-05) Yes No No — No/NA/NA Yes/Day 3 ACLF-2 Day 16 Multiorgan failure without
identifiable trigger
ACLF, acute-on-chronic liver failure; NA Q16.
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